Why Amylyx is pulling ALS drug Relyvrio from US market after study
Time:2024-05-07 14:52:04 Source:travelViews(143)
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Previous:Bank holiday booze
Next:2 killed when a small plane headed to South Carolina crashes in Virginia, police say
You may also like
- Detroit man sentenced to 80 years for fatal shootings of 2 West Virginia women
- Former senior Chongqing municipal legislator indicted for bribery
- Guideline unveiled to make public use of autonomous driving vehicles safer
- Former CSIC chairman sentenced to 13 years in jail for bribery, abuse of power
- An inquiry into a building fire in South Africa that killed 76 finds city authorities responsible
- China's anti
- People injured in earthquake get treatment in Gansu
- People injured in earthquake get treatment in Gansu
- Larrañaga, Kruger, Dunphy and Nolan to be honored with Joe Lapchick Character Award